Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin + rituximab vs investigator’s choice in relapsed/refractory CD22-positive aggressive NHL
jRCT2080221331Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2010
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), indolent lymphoma and 1 more (2 arms), sponsored by Pfizer. Started Dec 2010; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)indolent lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on jRCT2080221331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221331.